Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Summary

The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had disease progression and platinum-containing chemotherapeutic regimen.

Timeline

Start

2008-03

Primary completion

2012-02

Completion

2012-07

Outcome

Missed primary endpoint

registry analysis (superiority or other test); IMC-A12 (Cixutumumab) vs IMC-A12 (Cixutumumab) + Cetuximab; p = 0.0667; Log Rank NCT00617734 ↗

Drugs

Indications